DCprime and University of Bergen Present Data on Novel Animal Model for Cancer Vaccine Research

Presentation at EHA Congress reviews development of a humanized immunocompetent mouse model to study DCP-001 as a vaccine for leukemia

Leiden, The Netherlands, June 12, 2020DCprime, the front-runner in the field of relapse vaccines, in collaboration with the University of Bergen, today announced the presentation of a novel preclinical animal model tailored for cancer vaccine research at the virtual 25th European Hematology Association Congress (EHA). The humanized immunocompetent mouse model was applied to evaluate DCprime’s lead product DCP-001 as a standalone vaccine against leukemic cells, and will also enable future evaluation of DCP-001 in combination with chemotherapy or immune modulators. The full abstract and poster are available via the EHA Meeting’s website.

“This crucial animal model will be invaluable in advancing our pre-clinical knowledge of DCP-001 and its development could not have been accomplished without the expertise from our partners at the University of Bergen,” said Jeroen Rovers, MD, PhD, Chief Medical Officer of DCprime. “We look forward to working closely with Bergen University on future research initiatives as well as within the public-private consortium AML-VACCiN that continues to drive the clinical development of DCP-001 despite the current challenges in clinical practice due to COVID-19.”

“We are excited to support DCprime’s novel cancer relapse vaccine strategy as a potential future therapy to efficiently keep hematological cancers in check. Generating a mouse model that supports the xenograft of leukemic cell lines in conjunction with systemic engraftment of a human immune system, has been very instrumental to demonstrate the therapeutic potential of DCP-001 as a cell-based cancer vaccine,” commented Professor Bjørn Tore Gjertsen, Department of Clinical Science at the University of Bergen

DCprime’s lead cancer relapse vaccine candidate DCP-001 is generated by transforming a proprietary leukemic cell, DCOne®, into a whole cell-based cancer vaccine. Clinical data from a previously concluded phase 1 clinical study that was presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in December 2019 demonstrated DCP-001’s potential to prolong relapse-free survival and overall survival as an allogeneic, off-the-shelf cell-based vaccine in the post-remission setting.

DCP-001 is currently being evaluated in the international, multi-center, open-label proof-of-concept study ADVANCE-II with AML patients in complete remission, but with persistent measurable residual disease (MRD). The associated AML-VACCiN consortium receives support from the EU under the Horizon 2020 program. More information can be found at www.amlvaccin.eu.


For more information on the clinical trial, please visit: www.clinicaltrials.gov


About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product DCP-001 is a whole-cell based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/

Contact Information:

DCprime BV
Dr. Erik Manting
Phone: +31713322627
Email: e.manting@dcprime.com

Media Contact:
Mario Brkulj or Nicholas Chang
Phone: +49 175 5711562 or +1 781 235 3060
E-Mail: dcprime@macbiocom.com

Posted in PR